Evidence map›Paper›PMID 23087260›Full record

ArticleMolecular pharmacology2013

Extracellular loop II modulates GTP sensitivity of the prostaglandin EP3 receptor.

Chandramohan Natarajan, Aaron N Hata, Heidi E Hamm, Roy Zent, Richard M Breyer

Open access · bronzeAbstract read
In one paragraph

Article in Molecular pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Chandramohan NatarajanDivision of Nephrology, Vanderbilt University School of Medicine, S3223 MCN, 1161 21st Avenue, Nashville, TN 37232-2372, USA.
Aaron N Hata
Heidi E Hamm
Roy Zent
Richard M Breyer
Vanderbilt University · US

Funding

THE PHARMACOLOGY OF INHIBITORS OF HEME PROTEIN-CATALYZED LIPID PEROXIDATIONP50GM015431 · NIGMS · VANDERBILT UNIVERSITY · PI CAPRIOLI, RICHARD M · 1985 to 2010
$15.0M
TYPE IV COLLAGEN, LAMININS, AND INTEGRINS IN NORMAL AND DISEASED GLOMERULIP01DK065123 · NIDDK · VANDERBILT UNIVERSITY · PI HUDSON, BILLY GERALD · 2003 to 2012
$12.9M
IMMUNOLOGICAL STUDIES OF VISUAL TRANSDUCTION PATHWAYSR01EY006062 · NEI · VANDERBILT UNIVERSITY · PI HAMM, HEIDI E · 1985 to 2017
$5.6M
Regulation of Renal Function by PGE2 and PGF2a ReceptorsR01DK037097 · NIDDK · VANDERBILT UNIVERSITY · PI BREYER, RICHARD M. · 1986 to 2011
$3.9M
Betal Integrin and Renal TubulogenesisR01DK075594 · NIDDK · VANDERBILT UNIVERSITY · PI ZENT, ROY · 2008 to 2015
$2.6M
RENAL PROSTAGLANDIN E2 RECEPTORSR01DK046205 · NIDDK · VANDERBILT UNIVERSITY · PI BREYER, RICHARD M · 1993 to 2005
$1.5M
MINORITY PREDOCTORAL FELLOWSHIPF31DK009921 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI KARKASHIAN, CHRISTINE D · 1999 to 1999
–
Novel EP receptor antagonists for the treatment of hypertension and of diabetesI01BX000616 · VA · VETERANS HEALTH ADMINISTRATION · PI BREYER, RICHARD M. · 2011 to 2014
–
BLRD VA I01 BX000616NEI NIH HHS R01 EY006062NIDDK NIH HHS 2P01DK065123NIDDK NIH HHS DK075594NIDDK NIH HHS DK37097NIDDK NIH HHS DK46205NIDDK NIH HHS DK9921NIDDK NIH HHS F31 DK009921NIDDK NIH HHS P01 DK065123NIDDK NIH HHS R01 DK037097NIDDK NIH HHS R01 DK046205NIDDK NIH HHS R01 DK075594NIGMS NIH HHS P50 GM015431NIGMS NIH HHS P50GM015431
6 · The paper itself

Abstract

Unlike the majority of G protein-coupled receptors, the prostaglandin E(2) (PGE(2)) E-prostanoid 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of guanosine 5[prime]-O-(3-thio)triphosphate (GTPγS). We report the identification of mutations that confer GTPγS sensitivity to agonist binding. Seven point mutations were introduced into the conserved motif in the second extracellular loop (ECII) of EP3, resulting in acquisition of GTP-sensitive agonist binding. One receptor mutation W203A was studied in detail. Loss of agonist binding was observed on intact human embryonic kidney 293 cells expressing the W203A receptor, conditions where high GTP levels are present; however, high affinity binding [(3)H]PGE(2) was observed in broken cell preparations washed free of GTP. The [(3)H]PGE(2) binding of W203A in broken cell membrane fractions was inhibited by addition of GTPγS (IC(50) 21 ± 1.8 nM). Taken together, these results suggest that the wild-type EP3 receptor displays unusual characteristics of the complex coupled equilibria between agonist-receptor and receptor-G protein interaction. Moreover, mutation of ECII can alter this coupled equilibrium from GTP-insensitive agonist binding to more conventional GTP-sensitive binding. This suggests that for the mutant receptors, ECII plays a critical role in linking the agonist bound receptor conformation to the G protein nucleotide bound state.

Indexed as

AnimalsDinoprostoneGuanosine 5'-O-(3-Thiotriphosphate)HEK293 CellsHumansPoint MutationProtein ConformationRabbitsRadioligand AssayReceptors, Prostaglandin E, EP3 SubtypeSignal TransductionDinoprostoneGuanosine 5'-O-(3-Thiotriphosphate)Receptors, Prostaglandin E, EP3 Subtype

Identifiers

PMID23087260
PMCPMC3533480
OpenAlexW2155512829

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.